The company has shown impressive YoY revenue growth and improving profitability and margin, particularly aided by the BFSI and healthcare sectors. With expectations of double-digit revenue growth and EBITDA margin between 20-22% in the future, the company's prospects are bright. New transformational initiatives and investments in the GenAI business unit are expected to boost profitability. Additionally, the company's strong performance in the BFSI and healthcare segments, driven by new client acquisitions and a healthy pipeline, will likely...